FDA Drug Recalls

Recalls / Class II

Class IID-1513-2019

Product

Temozolomide Capsules, 250 mg, 5-count bottle, Rx only, Manufactured by: Deva Holding A.S., 1 Merkez Mahallesi, Istanbul, Turkey 34303, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-542-07.

Brand name
Temozolomide
Generic name
Temozolomide
Active ingredient
Temozolomide
Route
Oral
NDCs
67877-537, 67877-538, 67877-539, 67877-540, 67877-541, 67877-542
FDA application
ANDA207658
Affected lot / code info
Lot #: A062228, A062227, A062226, A062295, A062294, Exp 08/31/2019; A069325, A069323, Exp 05/31/2020; A072015, Exp 10/31/2020; A076611, A076609, A076608, A076607, Exp 04/30/2021

Why it was recalled

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Recalling firm

Firm
Deva Holding AS - Cerkezkoy Subesi
Manufacturer
Ascend Laboratories, LLC
Notification channel
E-Mail
Type
Voluntary: Firm initiated
Address
Organize Fatih Bulvar Fatih Bulvar 32 Cerkezkoy, N/A, Cerkezkoy, N/A N/A, Turkey

Distribution

Quantity
11472 bottles
Distribution pattern
Nationwide in the USA.

Timeline

Recall initiated
2019-07-16
FDA classified
2019-07-23
Posted by FDA
2019-07-31
Terminated
2022-01-06
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1513-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Temozolomide · FDA Drug Recalls